Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nanotech report

This article was originally published in The Tan Sheet

Executive Summary

A new report commissioned by the Project on Emerging Nanotechnologies at the Woodrow Wilson International Center for Scholars stresses the need for regulatory oversight of nanotechnology and provides a "roadmap" for the Environmental Protection Agency to handle the challenges of the science, study author J. Clarence Davies claims. The report presents an agenda to create an "effective oversight system" that includes changing areas within the EPA that deal with science, personnel, international activities and, program integration and evaluation. Released May 23, the 76-page report outlines 25 steps that EPA, the government, the U.S. National Nanotechnology Initiative and industry should take to improve oversight. "This new report seeks to encourage … an intelligent oversight approach that empowers EPA and promotes investment and innovation in new nanotechnology products and processes," PEN Director David Rejeski says...

You may also be interested in...



Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

Topics

UsernamePublicRestriction

Register

PS100547

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel